Dragonfly Therapeutics doses first patient in Phase 1/1b study of DF6215

Ascletis Pharma initiates ASC40 (Denifanstat) Phase III clinical trial to treat acne

Versameb names new chairman of the board

Kling Bio appoints Dr Stefano Gullà as chief scientific officer

ValiRx Plc licenses VAL401 to Ambrose Healthcare for rare disease treatments

ANGLE plc introduces Portrait+ CTC staining kit at San Antonio Breast Cancer Symposium

XNK Therapeutics announces presentation at DNB Nordic Healthcare Conference in Oslo

Syndax to discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

Immunitas Therapeutics appoints chief medical officer; Announces presentation at ASH 2023 Annual Meeting

Beacon Therapeutics presents positive three-month data for AGTC-501 in XLRP and plans pivotal Phase 2/3 VISTA trial

Everest Medicines's zetomipzomib investigational new drug application accepted by Chinese regulator

Telix Pharmaceuticals doses first patient in TLX250-CDx named patient (early access) program in Netherlands

280Bio treats first patient with advanced cancer harbouring mutations in KRAS, HRAS, or NRAS with TEB-17231

Everest Medicines announces positive topline data from multi-centre Phase three Etrasimod clinical trial in Asia

Clarity Pharmaceuticals starts registrational Phase III CLARIFY trial